Endpoint Health

Precision-first therapies

Y CombinatorWinter 2019InactiveHealthcareTherapeutics

What they do

Problem

Patients with immune-driven critical and chronic illnesses often receive ineffective one-size-fits-all therapies because treatments are not matched to individual biology.

Solution

Endpoint Health develops and commercializes personalized therapeutics and therapy-guiding diagnostic tests to target the right treatment to the right patient at the right time.

Who it's for

Clinicians and healthcare systems treating patients with immune-driven critical and chronic illnesses use its tests and therapies.

Founders

Diego Rey

Founder/CSO

Diego Rey, born in Bariloche, Argentina and now based in San Francisco, holds a BS (UCSB) in electrical engineering and PhD (Cornell) in biomedical engineering minoring in applied engineering physics and biophysics. He co-founded GeneWEAVE (acquired by Roche) and Endpoint Health (W19) developing rapid bacterial detection and immune disease therapeutics. Diego was the first bio Visiting Partner at YC. He Angel invests and serves on Cornell advisory councils.

LinkedIn · X